Siplizumab

Siplizumab
Monoclonal antibody
Type	Whole antibody
Source	Humanized (from rat)
Target	CD2
Clinical data
ATC code	none;
Identifiers
CAS Number	288392-69-8 ;
ChemSpider	none;
UNII	KUW1QG1ZM3;
KEGG	D05847 ;
	(what is this?) (verify)

Siplizumab (MEDI-507) is an investigational monoclonal antibody with a human IgG1, kappa directed to CD2. The agent has shown potent immunomodulatory effects, selectively suppressing the function of T and NK cells, and has been tested as a possible treatment for psoriasis and in the prevention of graft-versus-host disease.^[1]^[2]^[3]^[4]^[5]

References

^ Podestà, Manuel A.; Binder, Christian; Sellberg, Felix; DeWolf, Susan; Shonts, Brittany; Ho, Siu-Hong; Obradovic, Aleksandar; Waffarn, Elizabeth; Danzl, Nichole; Berglund, David; Sykes, Megan (January 2020). "Siplizumab selectively depletes effector memory T cells and promotes a relative expansion of alloreactive regulatory T cells in vitro". American Journal of Transplantation. 20 (1): 88–100. doi:10.1111/ajt.15533. PMC 6940533. PMID 31319439.
^ Langley, Richard G.; Papp, Kim; Bissonnette, Robert; Toth, Darryl; Matheson, Robert; Hultquist, Micki; White, Barbara (July 2010). "Safety profile of intravenous and subcutaneous siplizumab, an anti-CD2 monoclonal antibody, for the treatment of plaque psoriasis: results of two randomized, double-blind, placebo-controlled studies". International Journal of Dermatology. 49 (7): 818–828. doi:10.1111/j.1365-4632.2010.04512.x. PMID 20618506. S2CID 21145758.
^ O'Mahony, Deirdre; Morris, John C.; Stetler-Stevenson, Maryalice; Matthews, Helen; Brown, Margaret R.; Fleisher, Thomas; Pittaluga, Stefania; Raffeld, Mark; Albert, Paul S.; Reitsma, Dirk; Kaucic, Karen; Hammershaimb, Luz; Waldmann, Thomas A.; Janik, John E. (1 April 2009). "EBV-Related Lymphoproliferative Disease Complicating Therapy with the Anti-CD2 Monoclonal Antibody, Siplizumab, in Patients with T-Cell Malignancies". Clinical Cancer Research. 15 (7): 2514–2522. doi:10.1158/1078-0432.CCR-08-1254. PMC 7322623. PMID 19293260.
^ Adkins, Douglas; Ratanatharathorn, Voravit; Yang, Harry; White, Barbara (27 July 2009). "Safety Profile and Clinical Outcomes in a Phase I, Placebo-Controlled Study of Siplizumab in Acute Graft-Versus-Host Disease". Transplantation. 88 (2): 198–202. doi:10.1097/TP.0b013e3181abfbf7. PMID 19623014.
^ Cvetkovski, Filip; Razavi, Ronia; Sellberg, Felix; Berglund, Erik; Berglund, David (October 2023). "Siplizumab combination therapy with belatacept or abatacept broadly inhibits human T cell alloreactivity in vitro". American Journal of Transplantation. 23 (10): 1603–1611. doi:10.1016/j.ajt.2023.05.032. PMID 37270108.

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

[1] Podestà, Manuel A.; Binder, Christian; Sellberg, Felix; DeWolf, Susan; Shonts, Brittany; Ho, Siu-Hong; Obradovic, Aleksandar; Waffarn, Elizabeth; Danzl, Nichole; Berglund, David; Sykes, Megan (January 2020). "Siplizumab selectively depletes effector memory T cells and promotes a relative expansion of alloreactive regulatory T cells in vitro". American Journal of Transplantation. 20 (1): 88–100. doi:10.1111/ajt.15533. PMC 6940533. PMID 31319439.

[2] Langley, Richard G.; Papp, Kim; Bissonnette, Robert; Toth, Darryl; Matheson, Robert; Hultquist, Micki; White, Barbara (July 2010). "Safety profile of intravenous and subcutaneous siplizumab, an anti-CD2 monoclonal antibody, for the treatment of plaque psoriasis: results of two randomized, double-blind, placebo-controlled studies". International Journal of Dermatology. 49 (7): 818–828. doi:10.1111/j.1365-4632.2010.04512.x. PMID 20618506. S2CID 21145758.

[3] O'Mahony, Deirdre; Morris, John C.; Stetler-Stevenson, Maryalice; Matthews, Helen; Brown, Margaret R.; Fleisher, Thomas; Pittaluga, Stefania; Raffeld, Mark; Albert, Paul S.; Reitsma, Dirk; Kaucic, Karen; Hammershaimb, Luz; Waldmann, Thomas A.; Janik, John E. (1 April 2009). "EBV-Related Lymphoproliferative Disease Complicating Therapy with the Anti-CD2 Monoclonal Antibody, Siplizumab, in Patients with T-Cell Malignancies". Clinical Cancer Research. 15 (7): 2514–2522. doi:10.1158/1078-0432.CCR-08-1254. PMC 7322623. PMID 19293260.

[4] Adkins, Douglas; Ratanatharathorn, Voravit; Yang, Harry; White, Barbara (27 July 2009). "Safety Profile and Clinical Outcomes in a Phase I, Placebo-Controlled Study of Siplizumab in Acute Graft-Versus-Host Disease". Transplantation. 88 (2): 198–202. doi:10.1097/TP.0b013e3181abfbf7. PMID 19623014.

[5] Cvetkovski, Filip; Razavi, Ronia; Sellberg, Felix; Berglund, Erik; Berglund, David (October 2023). "Siplizumab combination therapy with belatacept or abatacept broadly inhibits human T cell alloreactivity in vitro". American Journal of Transplantation. 23 (10): 1603–1611. doi:10.1016/j.ajt.2023.05.032. PMID 37270108.

[1]

[2]

[3]

[4]

[5]